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Summary Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family, a novel
class of extracellular signal modulators. CCN2 is composed of four conserved modules connected in
tandem, each of which is rich in cysteines and highly interactive with other molecules. CCN2 has
various biological functions, being active in developmental processes including angiogenesis,
chondrogenesis, and osteogenesis. Recently CCN2 has gained more clinical interest due to its role
in cancer-induced bone destruction. In this article, the role of CCN2 in bone-destroying events as an
organizer of themicroenvironmental cell society is comprehensively described, anda brief summary
of the recent findings on regulatory factors involved in tumor-induced bone disease is given.
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Bone has been identified as a site of metastasis of cancer cells
of several common human malignancies, including breast,
prostate, multiple myeloma, and oral cancer [1—5]. The
clinical consequences of cancer-induced bone destruction
include aworse prognosis, physical damage by bone resection,
a high morbidity rate, intractable bone pain, pathological
fractures, and hypercalcemia [6]. Localization of tumor cells
within the bone leads to the production of tumor-associated
factors either synthesized directly by the tumor cell itself or as
a result of tumor/stromal interactions. These tumor-asso-
ciated factors converge on the pre-osteoblast or stromal cell
to cause an increase in the level of receptor activator of
nuclear factor kappa b ligand (RANKL) and/or a decrease in
that of osteoprotegerin (OPG), which ultimately results in
activation and survival of osteoclasts, with osteolytic lesions
being the result [7]. Osteolysis (process of bone resorption)
then leads to the release of growth factors derived from bone,
including transforming growth factor-b (TGF-b), insulin-like
growth factors (IGFs), fibroblast growth factors (FGFs), plate-
let-derived growth factor (PDGF), and bone morphogenetic
proteins (BMPs) [7,8]. These factors increase the production of
tumor-associated factors or promote tumor growth directly.
Thus, tumor cell proliferation and production of tumor-asso-
ciated factors through the signaling of these pathways are
promoted, and the cycle continues.Figure 1 CCN2-interacting proteins and biological functions of CC
CCN2. Interactions with growth factors, cell-surface signal-transdu
Biological functions of CCN2 in development. CCN2 is strongly express
chondrocytes in the growth plate of cartilage and has principal roleConnective tissue growth factor (CTGF/CCN2) belongs to
the CCN family [9], which consists of six members: CCN1
(Cyr61), CCN2 (CTGF), CCN3 (NOV), CCN4 (WISP-1), CCN5
(WISP-2), and CCN6 (WISP-3) [10—12], all of which possess an
NH2-terminal signal peptide indicative of their secreted-
protein nature. These proteins comprise distinct modules
in their structure, i.e., the insulin-like growth factor (IGF)-
binding protein-like module (IGFBP), von Willebrand factor
type C repeat (VWC), thrombospondin type-1 repeat (TSP1),
and C-terminal module (CT), except for CCN5, which lacks
the CT module. With these modules, the CCN2 protein inter-
acts with a number of extracellular molecules. The IGFBP
motif is responsible for binding IGF [13], albeit studies with
CCN2 have demonstrated that the interaction of CCN2 with
IGF has a much lower affinity than that of authentic IGFBPs
[14]. The VWC motif binds to integrin avb3 [15] and has been
implicated as a binding site for BMP-4 and transforming
growth factor-b (TGF-b) family members, this binding mod-
ulating their activity [16]. The TSP-1 motif is involved in
binding to integrin a6b1, avb3 [15], LRP1 [17], and VEGF
[18]. Finally, the CT motif binds integrin avb3 and cell-sur-
face heparan sulfate proteoglycans (HSPGs) [19]. These dif-
ferent domains of CCN2 could be responsible for the
differential signaling of its biological activities (Fig. 1A).
This review summarizes research on a new molecule,
CCN2, and related molecules that play essential roles in
the bone destruction caused by cancer.N2. (A) Interacting proteins and correspondence to modules of
cing receptors, and heparan sulfate proteoglycans (HSPGs). (B)
ed in the endothelial cells, mesenchymal cells, and hypertrophic
s in development.
Role of CCN2 in bone microenvironment 152. Physiological and pathological roles of
CCN2
2.1. Biological function of CCN2 in skeletal
development
CCN2 knockout mice die just after birth due to respiratory
failure [20]. This failure is attributed to hypoplasia of the
thoracic skeletonanddeformity of theoral cavity (palatal cleft
and shortened mandible). CCN2 knockout mice show skeletal
dysmorphisms as a result of impaired chondrocyte prolifera-
tion and reduced extracellular matrix composition within the
hypertrophic chondrocytic zone in the growth plate. Histolo-
gically, angiogenesis and formation of tartrate-resistant acid
phosphatase (TRAP)-positive osteoclast-like cells, as well as
critical protease expression in the growth plate, are impaired
and accompanied by defective replacement of cartilage by
bone during endochondral ossification. These results demon-
strate that CCN2 is important for cell proliferation and matrix
remodeling during chondrogenesis, and is a key regulator
coupling extracellular matrix remodeling to angiogenesis at
the growth plate. These activities are consistent with the
notion that recombinant CCN2 induces chondrocyte and osteo-
blast differentiation and proliferation in vitro [21—23], and
angiogenesis in vivo and in vitro [24,25]. The biological activ-
ities of CCN2 also include the development of Meckel’s carti-
lage [26] and tooth germs [27] (Fig. 1B).
2.2. Association of CCN2 in cancers
CCN2 is a secreted growth factor that can bind to integrins on
the cell surface [28], and elevated CCN2 expression has been
observed in breast cancers [29], pancreatic cancers [30],
melanomas [31], chondrosarcomas [32] and squamous cell
carcinomas [33]. Although CCN2 shows multiple roles in
various cancer types, in breast tumor cells CCN2 overexpres-
sion has been linked to an increase in tumor size, lymph node
metastasis [29,34], and drug resistance through up-regula-
tion of the survival pathway [35]. CCN2 is also regarded as a
central mediator of tumor angiogenic factor in certain malig-
nancies [36—38]. It should be noted that CCN2 is one of the
contributors to bone metastasis, as it converts low-meta-
static breast cancer cells to high-metastatic ones in the
collaboration with other factors [39,40]. Furthermore,
CCN2 gene was significantly overexpressed in overt meta-
static tumor cells as compared to disseminated tumor cells in
the bonemarrow of breast cancer patients by CT-guided bone
metastasis and bone marrow biopsy [41]. Fig. 2A and B shows
representative radiographs and immunohistochemical analy-
sis of hind limbs from mice 25 days after MDA-MB-231 cells
intracardiac inoculation. Obvious osteolytic lesions were
present in mice that had received control IgG, whereas very
few metastatic lesions were present in the mice treated with
the anti-CCN2 Ab at a dose of 100 mg/mouse twice per week
throughout the experiment (Fig. 2A). CCN2 and PTHrP were
strongly expressed in cancer cells that had invaded the bone
matrix, and these CCN2-expressing cells also expressed
PTH1R (Fig. 2B). Fig. 2C illustrates a representative radio-
graphic pattern of invasive bone destruction observed in a
patient with oral squamous cell carcinoma in the mandibular
region. CCN2 was abundantly produced by the tumor cellsthat had invaded the bone matrix (Fig. 2D) of note, up-
regulation of CCN2 in mandible oral squamous cell carcinoma
was associated with increased bone destruction [33]. These
data suggest that CCN2 can be considered a diagnostic
marker and target for treatment in oral osteolytic mandib-
ular squamous cell carcinoma.
3. The role of CCN2-regulating factors in
bone resorption
3.1. Parathyroid hormone-related protein
(PTHrP) induce CCN2 expression in bone
metastatic cancer cells
Parathyroid hormone-related protein (PTHrP) plays a vital
role in the development of the embryonic skeleton and other
tissues. When it is produced in excess by cancers, it can cause
hypercalcemia; and its local production by breast cancer
cells has been implicated in the pathogenesis of bone metas-
tasis in that disease. Localized production of PTHrP by cancer
cells in such lesions was shown to promote the survival and
proliferation of cancer cells and osteolysis in a mouse model
[42]. PTHrP induces both the production of RANKL and down-
regulation of OPG production by osteoblasts, thereby stimu-
lating osteoclastogenesis [43,44]. Type I PTH/PTHrP receptor
(PTH1R) expression was specifically observed in cancer cells
producing PTHrPand CCN2 invaded the bonemarrow (Fig. 2B)
and PTHrP strongly upregulated CCN2 in MDA-MB-231 cells in
vitro [45]. CCN2 was critically involved in osteolytic metas-
tasis and was induced by PKA- and PKC-dependent activation
of ERK 1/2 signaling by PTHrP [45].
3.2. Transforming growth factor-b (TGF-b) is one
of the most potent inducer of CCN2
Transforming growth factor-b (TGF-b) is by far the most
abundant cytokine in bone, 200 mg/kg tissue, and must be
considered as a central player in bone turnover [46] and
potentially able to couple bone resorption with bone for-
mation [47,48]. Restricted to the bone environment, target
cells include cancer cells as well as osteoblasts, osteoclasts,
their precursors bone marrow and stromal cells [46,47].
TGF-b is a pleiotropic cytokine that plays a central role in
maintaining epithelial homeostasis. In early carcinogenesis,
TGF-b acts as a tumor suppressor by inhibiting cell prolif-
eration [49,50]. However, several studies showed that pri-
mary tumor cells in the late stage could reprogram their
response to TGF-b by dysregulation or mutational inactiva-
tion of various components of the TGF-b signaling pathway
and through cross-interaction with other oncogenic path-
ways. Consequently, the TGF-b signal becomes a bone
metastasis-promoting one [51—53]. Blocking TGF-b signal-
ing especially in advanced stages of cancer may result in
beneficial therapeutic responses by inhibiting metastatic
progression [54]. TGF-b is one of the most potent inducers
of CCN2, promoting CCN2 expression in bone metastatic
cancer cells [39]; and the induction occurs through a com-
plex network of transcriptional interactions requiring
Smads, protein kinase C, and ras/MEK/ERK, as well as an
Ets-1/transcription enhancer factor binding element in the
CCN2 promoter [55—57].
Figure 2 Radiographic and immunohistochemical analysis of bone frommice bearing MDA-MB-231 or oral squamous cell carcinoma of
the mandibular region. (A) Representative radiographs of hind limbs from 25 days after tumor inoculation and treated with control IgG
or neutralizing CCN2 antibody (CCN2 AB). The arrowheads indicate osteolytic lesions. (B) Localization patterns of CCN2, PTHrP, or
PTH1R. Scale bar, 50 mm. (C) Representative radiograph of invasive oral squamous cell carcinoma in the mandibular region. (D)
Immunohistochemical staining of CCN2 in section of invasive pattern of resected mandible. Scale bar 200 mm. The data were modified
from Shimo et al. [45] (A and B) and Shimo et al. [33] (C and D). Bn: bone; Tm: tumor.
16 T. Shimo, A. Sasaki3.3. Bone marrow stromal and osteoblastic
cells-produced RANKL
The RANK/RANKL signaling pathway has been identified as
the key molecular basis for osteoclast-mediated bone resorp-
tion in both normal bone remodeling and in pathological
conditions, including bone metastasis [58—60]. RANK is a
transmembrane signaling receptor of the tumor necrosisfactor (TNF) receptor superfamily that is expressed on the
surface of osteoclast precursors [61,62]. Its cognate ligand,
RANKL, is expressed almost exclusively within the bone
marrow stromal cell compartment and is up-regulated by
most hormones and factors that stimulate bone resorption
[7,60]. The interaction of RANK and RANKL is necessary for
osteoclast formation, function, and survival [58,63]. RANKL
(50 ng/ml) stimulates osteoclastogenesis in mouse total bone
Figure 3 The hypothetical roles of CCN2 in the regulation of the bone microenvironment. Based on the finding obtained in vitro, the
possible interactions of CCN2 with integrin, proteoglycans, and growth factors involved in cancer metastasis bone. PG: proteoglycan.
Role of CCN2 in bone microenvironment 17marrow cells in the presence of 100 ng/ml CCN2 (Fig. 2D)
[33]. Stromal/osteoblastic cells are essential for in vitro
osteoclastogenesis through cell-to-cell interactions [64].
Therefore, it has been hypothesized that CCN2 may facilitate
cell-to-cell signaling by interacting with multiple molecules
on the surface of these cells through integrin [19,65], pro-
teoglycans [66], and growth factors [18].
3.4. Tumor-produced endothelin-1 (ET-1)
Tumor-produced endothelin-1 (ET-1) is also a key mediator of
osteoblastic bone metastasis, which is characteristic of
breast and prostate cancers [67,68]. CCN2 is one of the
secreted factors downstream of ET-1, as determined from
microarray analysis of osteoblasts [69]. ET-1 activates the
CCN2 promoter and induces CCN2 expression in cardiomyo-
cyte cells [70]. Furthermore, ET-1 induces CCN2 in an addi-
tive fashion to TGF-b through an element distinct from the
TGF-b response element [71—73].
4. General role and mechanism of CCN2 in
bone microenvironment
In the bone marrow microenvironment affected by tumor,
substantial bone marrow angiogenesis is present compared
with healthy persons [74]. In the case of the best-character-
ized CCN2, this factor is known to promote the proliferation
and differentiation of vascular endothelial cells as well as
fibroblasts and osteoblasts [22,24,25,75]. CCN2 protein is
able to interact with multiple molecules in the bone micro-
environment, thus resulting in the modulation of the extra
cellular molecular network therein. The angiogenic effects of
CCN2 is the results of the interaction with adhesion mole-
cules [19], cell-surface signal transducing receptors [76],
proteoglycans [66] and growth factors [18].
Bone-derived growth factors, such as TGF-b, FGFs, PDGFs,
BMPs, and IGF-1 are activated and released into the bone
microenvironment. Elevated TGF-b does not appear to affect
tumor growth, but rather leads to the production of PTHrP
[77] and CCN2 [39,45] in breast cancer cells, thus establishing
a continuously destructive cycle termed the ‘‘vicious cycle’’
through up-regulation of RANKL and accelerated boneresorption. Of note, CCN2 is known to interact with these
growth factors [16,18] or regulate the gene expression of
some of them [37]. As a result, CCN2 may be anticipated to
modulate the effects of these growth factors toward the
osteoblast induced RANKL and OPG expression, osteoclast
formation or osteoclast activation in bone metastasis region
(Fig. 3). The other critical function of CCN2 is exerted under
the interaction with extracellular matrix (ECM) molecules
and cell adhesion molecules. By interacting with integrins,
functions and other proteins and proteoglycans, CCN2 may
promote adhesion and migration of osteoclast precursor cells
and stimulate osteoclast formation and activation (Fig. 3).
CCN2 may be an integrator/modulator of extracellular infor-
mation and appears to allow the establishment and progres-
sion of the tumor angiogenesis and bone destruction within
the skeleton [78—80] (Figs. 3 and 4).
5. Therapeutic approaches
Suppression of bone-lesion development and limiting the
progression of an established bone metastasis should be
the primary goals of treating metastatic bone disease. Osteo-
clastic activity is the major contributor to cancer-induced
bone disease, and this cell type is an ideal target for thera-
pies. For instance, bisphosphonates have been widely and
successfully used for the treatment of bone metastases in
breast cancer and multiple myeloma patients [81—84], as
they block not only bone resorption but also tumor-cell
mitosis and additionally stimulate tumor-cell apoptosis [85].
5.1. OPG
The OPG/RANK/RANKL pathway offers multiple molecular
checkpoints for therapeutic targeting of osteolytic metas-
tases [86,87]. In a randomized, double-blind, phase-I clinical
trial, a single subcutaneous dose of the recombinant OPG
construct AMGN-0007 was effective in suppressing bone
resorption in breast cancer patients with established skeletal
metastasis [88]. Although AMGN-0007 had favorable pharma-
cokinetic and pharmacodynamic properties in the cancer
patient population, one potential risk with a recombinant
OPG molecule would be the generation of antibody titers
against the endogenous OPG protein.
Figure 4 Mechanisms of bone destruction in metastatic cancer. CCN2 is a newly recognized mediator in the vicious cycle. The cross-
talk between tumor cells and osteoclasts is not direct, but involves molecular and cellular intermediates; e.g., tumor cells secrete
parathyroid-hormone-related peptide (PTHrP), which is the primary stimulator of osteoblast production of RANKL [8]. PTHrP induces
CCN2 in tumor cells [33]; on the other hand, PTHrP up-regulates both the production of RANKL and down-regulates OPG production by
osteoblasts, thereby stimulating osteoclastogenesis [43]. Other factors produced and secreted by tumor cells (TNF-a, TGF-b,
macrophage colony-stimulating factor (M-CSF), IL-6, and prostaglandin E2) also increase the expression of RANKL. The increased
expression of RANKL in the tumor environment leads to increased formation, activation, and survival of osteoclasts cooperative
with these tumor-induced growth factors (CCN2, TNF-a, TGF-b, and M-CSF), resulting in osteolytic lesions. Osteolysis then leads to
the release of growth factors derived from bone, including transforming growth factor-b (TGF-b), insulin-like growth factors (IGFs),
fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and bone morphogenetic proteins (BMPs). These factors
increase the production of PTHrP or promote tumor growth directly. Bone destruction increases local extracellular calcium (Ca2+)
concentrations, which have also been shown to promote tumor growth and the production of PTHrP [8]. Thus, tumor cell
proliferation and production of tumor-associated factors through the signaling of positive-feedback pathways is promoted, thus
giving rise to a ‘‘vicious cycle.’’ Therapeutic approaches (highlighted in yellow) against bone microenvironment survival factors are
also indicated in the figure. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of the article.)
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RANKL inhibitor, denosumab (formerly AMG 162), has also
been developed and is being tested in the clinic. Denosu-
mab is a fully human monoclonal antibody against RANKL.
Phase-I and -II clinical trials have shown that denosumab
suppressed bone resorption in patients with malignant
bone disease stemming from multiple myeloma, prostate,
or breast cancer [89—91]. Denosumab was generally well
tolerated in those trials. No related serious adverse events
occurred. Furthermore, no patient had detectable anti-
denosumab antibodies. Another method to target RANKL
includes an osteoprotegerin-like peptidomimetic (OP3-4),
which was demonstrated to be capable of inhibiting
myeloma bone disease in vivo model [92]. No clinical
results using these latter strategies have been presented
to date.
5.3. PTHrP
PTHrP antibodies neutralize PTHrP and vitamin-D analogues
and decrease PTHrP production [93]. PTHrP neutralizing
antibodies are therapeutically effective in animal models
of the humoral hypercalcemia of malignancy and those of
bone metastasis [94,95].5.4. Src
Because of the role of Src in both cancer development and in
bone metabolism, it may provide a therapeutic target for
patients with bone metastases. Dasatinib (SPRYCEL, Bristol-
Myers Squibb, New York) is a small-molecule tyrosine kinase
inhibitor with activity against several signaling proteins [96].
Dasatinib is now being evaluated in phase-I and II trials in a
variety of tumor types, including prostate and lung cancers
[97,98]. AZD-0530 is an another dual Src/Abl inhibitor that
has been shown to inhibit the formation and activity of
human osteoclasts, as well as to suppress tumor growth
and metastasis [89].
5.5. ET-1
Specific inhibitors of ET-1 signaling (antagonists of the
endothelin-A receptor [ETAR]) have beneficial effects on bone
metastatic lesions arising from prostate cancer [99]. Selective
ETAR antagonists may block the proliferative effects of exo-
genous ET-1 on both prostate cancer cells and osteoblasts.
More specifically, Atrasentan (ABT-627), an antagonist of
ETARs,may inhibit tumor growth in bone both by direct effects
on the tumor cells and by destroying important bone/tumor
interactions [100—102]. ZD4054, a specific ETA antagonist, is
Role of CCN2 in bone microenvironment 19being examined currently in phase-II studies on prostate can-
cer, little data on its efficacy has been reported, but an
improvement was seen in overall survival [103].
5.6. Radionuclide
Radionuclide therapy is a useful and cost-effective means of
alleviating bone pain in metastatic disease and may be more
effective when combined with chemotherapy, bisphospho-
nates, and radiation therapy [104,105]. Due to the chemical
similarity between strontium and calcium, 89Sr (Metastron1)
is preferentially retained in the skeleton, especially in areas
of rapid osteoblastic activity and bone formation associated
with tumor-mediated bone remodeling by a factor of about
10 versus its retention in healthy bone [104]. 153Sm-EDTMP
(Quadramet1) is most widely used in the United States to
relieve pain from bone metastasis, with palliation occurring
in 65—80% of patients with better overall response rates at
higher doses in early phase-I and -II studies [105]. 153Sm is
administered with a large excess of a bone targeting phos-
phonate-chelating agent [lexidronam or ethylenediaminete-
tramethylenephosphonate (EDTMP)] to enable delivery of
the injected 153Sm to areas of bone formation. The absorp-
tion of this radiopharmaceutical is 17 times faster in lesions
than in normal bone, and due to its rapid renal clearance,
nonosseous radioactive exposure is low [106].
6. Conclusions
Osteoclastogenesis and angiogenesis is the most fundamental
step leading to tumor-induced bone destruction. Based on
the accumulating data in vitro and the phenotypic change
observed in the CCN2 KO mice, CCN2 is now believed to be
such a central modulator of extracellular signaling and mole-
cular architecture in the endochondral ossification process.
Final stage of endochondral ossification is the most funda-
mental step for osteoclast activation and angiogenesis from
bone marrow. From a clinical point or view, osteoclast and
angiogenesis is one of the major targets of tumor bone
metastasis (Fig. 4). Unlike tumor growth, the major modu-
lator of this process has been shown to be the CCN2molecule,
which is thus now regarded as a potential target of anti-
osteoclastogenic and angiogenic therapy [45,107]. In fact,
recent studies have shown that CCN2 stimulated TRAP-posi-
tive osteoclast-like cell formation in bone marrow cell cul-
ture [33]. Therefore, an anti-CCN2 strategy may provide a
safer choice without adverse effects than those with other
osteoclast targeted agents. CCN2 may be able to apply for
molecular target therapy of bone metabolic and resorptive
disease such as osteoporosis and periodontitis.
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